4DMedical Ltd
ASX:4DX
4DMedical Ltd
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-08-07. The firm is focused on development of a non-invasive respiratory imaging solution using four-dimensional imaging. The firm's XV Technology is a four-dimensional lung imaging technology that utilizes mathematical models and algorithms to convert X-ray scans into quantitative data for physicians to manage patients with respiratory diseases and diseases of the lung. The XV Technology is accessible through a cloud-based software as a service (SaaS) platform that integrates with existing hospital equipment. The XV Technology Lung Ventilation Analysis Software (XV LVAS Ventilation) provides a non-invasive way of understanding regional lung motion and airflow. The company enables physicians to detect areas of high and low ventilation from all parts of the lung, in all phases of the breath.
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-08-07. The firm is focused on development of a non-invasive respiratory imaging solution using four-dimensional imaging. The firm's XV Technology is a four-dimensional lung imaging technology that utilizes mathematical models and algorithms to convert X-ray scans into quantitative data for physicians to manage patients with respiratory diseases and diseases of the lung. The XV Technology is accessible through a cloud-based software as a service (SaaS) platform that integrates with existing hospital equipment. The XV Technology Lung Ventilation Analysis Software (XV LVAS Ventilation) provides a non-invasive way of understanding regional lung motion and airflow. The company enables physicians to detect areas of high and low ventilation from all parts of the lung, in all phases of the breath.
Revenue Growth: 4DMedical reported a 16.5% half-to-half revenue increase, with a $6 million recurring revenue run rate, though recent contract wins are not yet fully reflected in these numbers.
Cost Management: Operating expenditure dropped by 11% half-on-half, and management says the company is well past its peak spending.
Capital Raising: The company is completing a $12.5 million placement and SPP, structured to potentially bring in $30 million in total, aimed at funding the business through to breakeven.
Philips Partnership: The Philips reseller agreement is expected to bring contracts and meaningful revenue before June 30, with Philips' 250 salespeople now selling 4DMedical products.
Product Momentum: Recent FDA approval and $650 Medicare reimbursement for IQ-UIP, as well as growth in scan volumes, sites, and average price per scan, are driving momentum.
Australia and U.S. Trends: U.S. revenue is rising significantly; Australian revenue appeared to drop due to a legacy contract rolling off, but underlying business there has grown by 40% recently.
VQ Product Launch: The upcoming VQ product is positioned as a superior, logistically easier alternative to nuclear medicine VQ scans, targeting a $1 billion U.S. market.
